IMM Immupharma Plc

TIDMIMM

RNS Number : 7664L

Immupharma PLC

30 April 2015

 
  30 APRIL 2015 
 

DR STÉPHANE MÉRY APPOINTED AS NON-EXECUTIVE DIRECTOR

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the appointment of Dr Stéphane Méry as non-executive director.

Dr Stéphane Méry has extensive experience in the Healthcare industry. He is currently CEO of Contronics Ltd, which designs and sells laboratory monitoring equipments, and until recently he was Partner at Beringea LLP, a $400m US/UK venture capital fund, where he was responsible for healthcare investments in Europe. Previously, he was the Fund Manager/CEO of the Bloomsbury Bioseed Fund, a Biotech and Medtech investment fund, which was behind the birth of successful companies such as Spirogen (sold to MedImmune), Abzema (listed on AIM), and Canbex, (recently sold to Ipsen). Prior to this, Stéphane was Associate Director, Worldwide Business Development, for SmithKline Beecham (GSK) where he was responsible for the negotiation of several major in-license deals and acquisitions. Before GSK, he was involved in the start-up of Double Helix Development, a successful strategic consultancy company specialising in R&D for the biotech and healthcare industry and recently sold to McCann. Just before, he worked as a management consultant at the American consultancy firm, ZS Associates, specialising on sales and marketing within the pharmaceutical industry. Stéphane is a Doctor in Veterinary Medicine, a trained Veterinary Pathologist, specialising in Nasal Toxicology at the Chemical Industry Institute of Toxicology (CIIT) in North Carolina, and holds an MBA from INSEAD (Fontainebleau).

Commenting on Dr Méry's appointment Richard Warr, Executive Chairman said:

"The appointment of Dr Stéphane Méry represents a strong addition to the Board. Stéphane's industry background and investment experience will be very valuable as we embark on the pivotal Phase III trial for Lupuzor(TM) ."

Stéphane Robert George Méry, age 50

 
 Current Directorships        Previous Directorships (held 
                               within the past five years) 
 Contronics Limited           Abzena plc 
  Contronics (Holdings)        Altacor Limited 
  Limited                      APM Healthcare Limited 
  La Petite Ecole Francaise    Beringea LLP 
  Ltd                          Canbex Therapeutics Limited 
                               Disposable Cubicle Curtains 
                               Limited 
                               Digital Healthcare Ltd 
                               Domainex Limited 
                               Endomagnetics Ltd 
                               Genex Biosystems Limited 
                               Inforsense Ltd 
                               Long Eaton Healthcare Ltd 
                               NCE-Discovery Limited 
                               Omni Dental Sciences Limited 
                               Pharmovation Limited 
                               Polytherics Limited 
                               Population Genetics Technologies 
                               Limited 
                               ProAxon Limited 
                               Spear Therapeutics Limited 
 

Stéphane Méry holds 2,259 ordinary shares in the Company.

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

For further information please contact:

 
                                            + 44 (0) 20 
 ImmuPharma plc                               7152 4080 
 Dimitri Dimitriou, Chief Executive 
  Officer 
 Dr Robert Zimmer, President and 
  Chief Scientific Officer 
 Richard Warr, Chairman 
 Lisa Baderoon, Head of Investor          + 44 (0) 7721 
  Relations                                      413496 
 
 Panmure, Gordon & Co., NOMAD &         +44 (0) 20 7886 
  Broker                                           2500 
 Hugh Morgan, Fred Walsh, Duncan 
  Monteith, Corporate Finance 
  Charles Leigh-Pemberton, Corporate 
  Broking 
 
 
 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAPKCDQABKDFQB

Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024